STAT Plus: New York biotech debuts, targeting dormant metastatic cancer cells
ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME
HiberCell, which has raised roughtly $60 million, calls itself the first company exclusively focused on the detection and treatment of dormant tumor cells.
No hay comentarios:
Publicar un comentario